#Sweden #Stockholm #Warrants #SciBase #Rights Issue

Recalculation of SciBase's Series TO 2 Warrants

On January 27, 2025, SciBase Holding AB, a prominent player in the medical technology field, released details regarding the recalculation of its series TO 2 warrants. These changes are a follow-up to a rights issue announced on November 12, 2024, which aimed to bolster the company's capital.

According to the specifics laid out in the terms and conditions of the warrants, the subscription price per share associated with the TO 2 warrants remains constant at SEK 0.42. Each warrant still grants the holder the right to subscribe for one new share in the company. This subscription period is set to run from April 3, 2029, until April 17, 2029. The company confirmed that the recalculation did not alter the number of shares each warrant gives the holder the right to purchase, maintaining the previous agreement's integrity.

Background on the Company

SciBase is recognized for its innovative work in dermatology, specifically in the early detection and prevention of skin conditions. The company’s flagship product, Nevisense, utilizes advanced artificial intelligence and Electrical Impedance Spectroscopy (EIS) technology to improve the diagnostic precision of skin disorders. Founded on over two decades of research from the Karolinska Institute in Stockholm, SciBase is committed to improving skin health management.

In light of the current recalibration process, SciBase's warrant holders can be assured that their rights to convert these warrants into shares remain clearly defined, which is crucial for maintaining investor confidence. Additionally, the company has emphasized its pledge to minimize patient suffering while ensuring that medical professionals can intervene early, ultimately leading to better health outcomes and reduced healthcare costs.

Looking Ahead

As SciBase continues to innovate and expand its offerings, the recalibration of the TO 2 warrants reflects its strategic financial management. Investors interested in the biotech sector should monitor how these developments may influence the company’s market performance and investor engagement. Given the company's strong commitment to advancing dermatological care, it remains a focal point for shareholders and potential investors alike.

The terms and conditions of the series TO 2 warrants, including any future adjustments due to further share issues, are readily accessible on SciBase's official website. This transparency is part of the company's dedication to informing investors about their holdings and opportunities.

For further inquiries, interested parties are encouraged to reach out directly to Pia Renaudin, the CEO of SciBase, via the contact information provided in their official communications.

Conclusion

The recent recalculation of SciBase’s series TO 2 warrants is a crucial development for both the company and its investors. With unchanged terms and a proactive approach to investor relations, SciBase aims to maintain a strong position in the growing medical technology market, dedicated to improving patient outcomes through early detection and intervention in dermatological care.